Answers are grounded in this paper and cite their sources.
Lenacapavir is a first‐in‐class HIV‐1 capsid inhibitor with long‐acting pharmacokinetics that enable 6‐monthly subcutaneous dosing after initiation with oral lead‐in. Lenacapavir is a CYP3A4, UGT1A1 and P‐gp substrate; inducers of these enzymes and P‐gp can significantly decrease lenacapavir concentrations. In patients receiving lenacapavir for HIV pre‐exposure prophylaxis (PrEP), supplemental lenacapavir doses can be administered if rifabutin (moderate inducer) or rifampin (potent inducer) are initiated. However, these recommendations have not been extended to lenacapavir when used for HIV treatment, and little is known about initiating lenacapavir in patients on stable therapy with inducers. We describe a 30‐year‐old man with advanced HIV infection and disseminated Mycobacterium avium complex infection receiving rifabutin and concurrent darunavir/ritonavir in whom lenacapavir was initiated with a 50% increase in both oral (900 mg on Days 1 and 2) and subcutaneous loading doses (1390.5 mg on Day 1). Therapeutic drug monitoring using validated UPLC–MS/MS method demonstrated that lenacapavir plasma concentrations remained above the target of 15.5 ng/mL (4× protein‐adjusted 95% effective concentration [PA‐EC 95 ]) over the dosing interval, with C max of 245.7 ng/mL and a projected C min of 19.5 ng/mL at 6 months. HIV viral load remained suppressed. This case demonstrates that dose‐adjusted lenacapavir can achieve therapeutic exposures in the presence of pre‐existing moderate induction. These findings provide clinically relevant pharmacological insight to support the use of lenacapavir in complex patients requiring rifamycin therapy.
No takes yet. Share an insight, caveat, or question.
McIntyre et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: